Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, phase II, open-label, single-arm investigator initiated trial to
evaluate the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic
HER2 negative breast cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University